Circulation: Cardiovascular Interventions最新文献

{"title":"Clinical Experience With a Novel Percutaneous LV Assist Device in High-Risk PCI: Primary Results From the SUPPORT I Study.","authors":"David E Kandzari, Andrea Mignatti, Annapoorna Kini, Garrett Wong, Gagan Singh, Azeem Latib, Ricardo Costa, Carlos M Campos, Alexandre Abizaid","doi":"10.1161/CIRCINTERVENTIONS.125.016010","DOIUrl":"10.1161/CIRCINTERVENTIONS.125.016010","url":null,"abstract":"<p><strong>Background: </strong>An early feasibility study was conducted to evaluate the performance of a low-profile, microaxial percutaneous ventricular assist device (pVAD; Supira Medical, Los Gatos, CA) capable of up to 5.5 L/min flow to provide hemodynamic support in high-risk percutaneous intervention (PCI).</p><p><strong>Methods: </strong>A prospective, single-arm feasibility study using the Supira pVAD in high-risk PCI was performed at 4 centers in the United States. The primary feasibility end point was defined as successful initiation and maintenance of hemodynamic support without sustained hypotension or need for alternative mechanical circulatory support. The primary safety end point was the occurrence of major device-related adverse events attributed to the study device or procedure from the time of device insertion to removal.</p><p><strong>Results: </strong>Fifteen patients underwent elective high-risk PCI with hemodynamic support using the Supira pVAD system. Multivessel PCI was performed in 80% of cases, including unprotected left main revascularization (67%) and atherectomy and intravascular lithotripsy (60%). Technical and procedural success rates were 93.3% and 86.7%, respectively. The primary feasibility end point was achieved in all 15 patients (100%). The primary safety end point occurred in 1 patient (6.7%). By 90 days, there were 2 deaths unrelated to the study device. There were no bleeding events, vascular/limb complications requiring intervention, cardiac structural/valve injury, or stroke attributed to the study device.</p><p><strong>Conclusions: </strong>As an early feasibility study, treatment with the Supira pVAD demonstrated favorable performance and device-related safety. These findings add to existing experience with the Supira pVAD to support a forthcoming pivotal trial in high-risk PCI.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT06087575.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016010"},"PeriodicalIF":7.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response by Zhou et al to Letter Regarding Article, \"Ultra-Low-Dose Noise-Free Technology to Reduce Radiation Exposure During Coronary Angiography\".","authors":"Jinying Zhou, Zhangwei Chen, Chenguang Li","doi":"10.1161/CIRCINTERVENTIONS.126.016971","DOIUrl":"10.1161/CIRCINTERVENTIONS.126.016971","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016971"},"PeriodicalIF":7.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148041360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.","authors":"Kashish Goel, Brian R Lindman, Allan Schwartz, David J Cohen, Gennaro Giustino, J Bradley Oldemeyer, Justin Strote, Vasilis Babaliaros, Chandan M Devireddy, Michael P Fischbein, William F Fearon, David Daniels, Christian Spies, Adnan K Chhatriwalla, Hussam S Suradi, Pinak Shah, Molly Szerlip, Thom Dahle, Dimitrios Apostolou, Raj Makkar, Charles J Davidson, Tej Sheth, Paul Sorajja, James T DeVries, Jeffrey Southard, Jeremiah P Depta, Andrei Pop, Michael J Rinaldi, Salem Badr, Mathew R Williams, Mark J Russo, Mayra Guerrero, James M McCabe, Philippe Pibarot, Yizhuo Wang, Martin B Leon, Philippe Généreux","doi":"10.1161/CIRCINTERVENTIONS.125.016370","DOIUrl":"10.1161/CIRCINTERVENTIONS.125.016370","url":null,"abstract":"<p><strong>Background: </strong>The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus CS strategy by age is unknown.</p><p><strong>Methods: </strong>The study population of the EARLY TAVR trial was stratified into 4 age groups: 65 to 69 years (n=141), 70 to 74 years (n=263), 75 to 79 years (n=250), and ≥80 years (n=247). Associations between age and the trial primary end point of death, stroke, or unplanned cardiovascular hospitalization; the composite end point of death, stroke, or heart failure hospitalization; and its individual components were examined. Interaction tests evaluated whether the treatment effect of early TAVR versus CS differed by age.</p><p><strong>Results: </strong>No interaction was detected between age and the treatment effect of early TAVR versus CS for the composites or individual outcomes. We observed lower stroke rates with early TAVR compared with CS in the youngest (65-69 years, absolute risk reduction, 13%; <i>P</i>=0.008) and oldest (≥80 years; absolute risk reduction, 12.3%; <i>P</i>=0.029) age groups. The absolute difference in heart failure hospitalization rates between the early TAVR and CS arms at 2 years was greatest in the oldest patients (≥80 years, 9.1%; 75-79 years, 5.9%; 70-74 years, 5.1%; 65-69 years, 4.4%). In the CS group, time to conversion to AVR was similar across all age groups (median, 11 months; <i>P</i>=0.73). Approximately one-third of younger patients (65-69 years) in the CS arm presented with acute valve syndrome at the time of conversion, the frequency of which tended to increase with age (<i>P</i>=0.06).</p><p><strong>Conclusions: </strong>In the EARLY TAVR trial, the relative benefit of early TAVR over CS was consistent among all age groups. The greatest absolute reduction in stroke rate with early TAVR compared with CS appeared in the youngest and oldest groups, whereas reduction in heart failure hospitalization was most pronounced in the oldest patients. These data suggest that early TAVR should be considered in all age groups above 65 years.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT03042104.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016370"},"PeriodicalIF":7.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.","authors":"Quentin Fischer, Isabelle Nault, Pedro Cepas-Guillén, Marisa Avvedimento, Carla Benavent-Garcia, Emilie Pelletier-Beaumont, François Philippon, Josep Rodés-Cabau","doi":"10.1161/CIRCINTERVENTIONS.125.016288","DOIUrl":"10.1161/CIRCINTERVENTIONS.125.016288","url":null,"abstract":"<p><strong>Background: </strong>Although ambulatory ECG (AECG) monitoring has been assessed after transcatheter aortic valve replacement (TAVR), its impact on life-threatening cardiovascular events remains unclear. This study aimed to evaluate whether systematic AECG monitoring after TAVR reduces life-threatening cardiovascular events during the first year of follow-up.</p><p><strong>Methods: </strong>The study included 1217 consecutive patients who underwent TAVR and were discharged without a permanent pacemaker. Of these, 211 consecutive patients received systematic 14-day AECG monitoring at discharge as part of the RECORD (Assessment of Arrhythmic Burden With Post-Procedural Continuous Electrocardiographic Monitoring in Patients Undergoing Transcatheter Aortic Valve Implantation) registry. The remaining 1006 patients who underwent TAVR within the 3 years before and after the registry period without systematic AECG monitoring constituted the control group. The primary end point was a composite of sudden cardiac death, syncope/presyncope due to symptomatic arrhythmias, or stroke at 1-year.</p><p><strong>Results: </strong>Baseline and procedural characteristics were similar between groups, except for a higher use of self-expandable valves in the control group (<i>P</i>=0.005). Systematic AECG monitoring was associated with a lower incidence of the primary endpoint (1.9% versus 6.6%; adjusted hazard ratio, 0.27 [0.10-0.74]; <i>P</i>=0.011), mainly driven by a lower rate of sudden death or arrhythmic syncope/presyncope (0.9% versus 4.0%; adjusted hazard ratio, 0.22 [0.05-0.89]; <i>P</i>=0.034). All sudden death cases occurred in the control group, at a median of 96 (33-235) days after TAVR. New-onset atrial fibrillation was diagnosed in 8.9% of the systematic AECG patients (versus 1.8% in the control group; adjusted hazard ratio, 5.31 [2.47-11.38]; <i>P</i><0.001), leading to new oral anticoagulation in 71.4% of cases. Stroke and permanent pacemaker implantation rates at 1 year were similar between groups, although permanent pacemaker implantation occurred earlier in the AECG group (25 versus 104 days; <i>P</i><0.001).</p><p><strong>Conclusions: </strong>Systematic AECG monitoring after TAVR enabled earlier detection of severe arrhythmias and was associated with fewer life-threatening cardiovascular events within 1 year. These findings support the need for a randomized trial.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT04298593.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016288"},"PeriodicalIF":7.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Aortic Root Rupture in Bicuspid Aortic Stenosis: The ABC Sizing Algorithm for SAPIEN 3 Valves.","authors":"Tej Sheth, Josep Rodés-Cabau, Karl Poon, Jean Michel Paradis, Neil Fam, Dale Murdoch, Sami Al-Nasser, Mann Chandavimol, Jorge Chavarria, Alexander Dick, Anna Bizios, Pantelis Diamantouros, Jonathan Yap, Andrew Chatfield, Abdul-Rahman Ihdayhid, Sonny Palmer, Norman Said Vega, James Velianou, Sameer Parpia, Muhammad Suleman","doi":"10.1161/CIRCINTERVENTIONS.126.016918","DOIUrl":"10.1161/CIRCINTERVENTIONS.126.016918","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the ability of the ABC Bicuspid Sizing Algorithm to predict aortic root rupture in patients treated with transcatheter aortic valve replacement using SAPIEN 3 valves.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter study among 15 centers in 7 countries of aortic root rupture cases and controls without root complications. Computed tomography analysis was performed blinded to rupture status. The ABC algorithm was applied to classify risk (high-risk criteria): (1) annular oversizing >10%, (2) intercommissural distance - valve diameter ≤1 mm, (3) maximum sinus diameter - valve diameter <6 mm alone, or (4) maximum sinus diameter - valve diameter 6 to 8 mm with contrast calcium volume >1000 mm³ and raphe + contralateral or ipsilateral leaflet calcium volume >800 mm³, (5) protruding nodular intercommissural distance calcium or full-length calcification of both leaflet edges.</p><p><strong>Results: </strong>A total of 170 patients were included (23 ruptures and 147 controls). Cases exhibited higher total calcium volume (median: 1498 mm³ versus 826 mm³; <i>P</i><0.001), smaller intercommissural distance difference (median: -0.15 versus 1.19 mm; <i>P</i>=0.009), smaller maximum sinus difference (median: 6.79 versus 9.19 mm; <i>P</i><0.001), and greater annular oversizing (median: 6.57% versus 3.51%; <i>P</i>=0.047). The presence of any high-risk criterion had a sensitivity of 100% (95% CI, 85.7%-100%) and a specificity of 89.1% (95% CI, 83.1%-93.2%) for the identification of rupture cases. The diagnostic odds ratio was 374.5 (95% CI, 21.7-6459.9), with a positive likelihood ratio of 9.19 and a negative likelihood ratio of 0.023.</p><p><strong>Conclusions: </strong>High calcium volume, narrow sinus dimensions, and excessive valve oversizing were associated with aortic root rupture. The ABC algorithm showed promising performance for risk stratification of patients with bicuspid anatomy being considered for treatment with a SAPIEN 3 valve.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016918"},"PeriodicalIF":7.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148327246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Feasibility Study of a Novel Mechanical Circulatory Support Device for High-Risk PCI.","authors":"Kevin J Croce, Ajay J Kirtane, Matthias Götberg, David E Kandzari, Brian A Bergmark, Hector Tamez, Margaret McEntagart, Andrew J P Klein, Rafael Cavalcante, Robert W Yeh","doi":"10.1161/CIRCINTERVENTIONS.125.016457","DOIUrl":"10.1161/CIRCINTERVENTIONS.125.016457","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016457"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13384374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Revascularization in STEMI With MVD: Defined Intervention, But When Exactly?","authors":"Michele Strosio, Salvatore Brugaletta","doi":"10.1161/CIRCINTERVENTIONS.126.016981","DOIUrl":"10.1161/CIRCINTERVENTIONS.126.016981","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016981"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148027767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation.","authors":"Cristina Aurigemma, Giuliano Costa, Giulia Laterra, Thomas Pilgrim, Ignacio J Amat Santos, Ole De Backer, Won-Keun Kim, Henrique Barbosa Ribeiro, Francesco Saia, Matjaz Bunc, Didier Tchetche, Philippe Garot, Flavio Luciano Ribichini, Darren Mylotte, Yusuke Watanabe, Francesco Bedogni, Tullio Tesorio, Tobias Rheude, Gennaro Sardella, Marco Tocci, Anna Franzone, Roberto Valvo, Sofia Sammartino, Mikko Savontaus, Hendrik Wienemann, Italo Porto, Caterina Gandolfo, Alessandro Iadanza, Markus Mach, Azeem Latib, Luigi Biasco, Maurizio Taramasso, Federico De Marco, Valentina Frittitta, Elena Dipietro, Claudia Reddavid, Orazio Strazzieri, Federica Agnello, Alessandro Comis, Mariachiara Calì, Mohamed Abdel-Wahab, Giulio Giuseppe Stefanini, Daijiro Tomii, Philippe Nuyens, Lars Sondergaard, Alessandro S Bortone, Marco Zimarino, Sergio F Camara, Tullio Palmerini, Mateusz Orzalkiewicz, Klemen Steblovnik, Alexandre Gautier, Paolo Alberto Del Sole, Andrea Mainardi, Mattia Lunardi, Hideyuki Kawashima, Enrico Criscione, Vincenzo Cesario, Fausto Biancari, Federico Zanin, Giovanni Esposito, Matti Adam, Eberhard Grube, Stephan Baldus, Vincenzo De Marzo, Elisa Piredda, Stefano Cannata, Fortunato Iacovelli, Martin Andreas, Domenico Angellotti, Carmelo Sgroi, Erion Xhepa, Faraj Kargoli, Corrado Tamburino, Francesco Burzotta, Marco Barbanti","doi":"10.1161/CIRCINTERVENTIONS.125.015770","DOIUrl":"10.1161/CIRCINTERVENTIONS.125.015770","url":null,"abstract":"<p><strong>Background: </strong>The best management of coronary artery disease in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) is debated. We investigated the clinical impact of the residual extent of myocardium at risk in patients undergoing TAVI.</p><p><strong>Methods: </strong>Patients enrolled in the REVASC-TAVI (Management of Myocardial Revascularization in Patients Undergoing TAVI With Coronary Artery Disease) international multicenter registry were stratified according to the myocardium jeopardized by coronary artery disease using the British Cardiovascular Intervention Society Jeopardy Score (BCIS-JS) after a planned coronary revascularization. A planned revascularization included percutaneous coronary interventions performed before TAVI, during TAVI, or within 1 month after TAVI. The study population was divided according to the residual BCIS-JS (rBCIS-JS): patients with extensive residual myocardial at risk (rBCIS-JS >4 group) and patients without extensive residual myocardial at risk (rBCIS-JS ≤4 group). The primary study end point was the composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and rehospitalization for heart failure at 2 years.</p><p><strong>Results: </strong>Among the 2407 patients enrolled, 294 pairs of patients were selected by propensity matching and compared. At 2-year follow-up, the incidence of the primary end point was higher in patients with rBCIS-JS >4 compared with patients with rBCIS-JS ≤4 (37.5% versus 23.0%, <i>P</i>=0.004). A significantly lower rate of myocardial infarction was reported in patients with BCIS-JS ≤4 (8.2% versus 2.6%, <i>P</i>=0.011). At multivariate analysis, rBCIS-JS >4 (hazard ratio, 1.43 [95% CI, 1.11-1.84]; <i>P</i>=0.005) independently predicted 2-year major adverse cardiac and cerebrovascular events.</p><p><strong>Conclusions: </strong>In patients with concomitant coronary artery disease and severe aortic stenosis, the residual myocardial risk significantly affects TAVI outcomes. In particular, a rBCIS-JS >4 is associated with higher rates of major adverse cardiac and cerebrovascular events at 2 years.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e015770"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13384366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses.","authors":"Mark J Zorman, Kaleb Foster, Bas L Kietselaer, Mayra E Guerrero, Charanjit S Rihal, Mackram F Eleid","doi":"10.1161/CIRCINTERVENTIONS.125.016270","DOIUrl":"10.1161/CIRCINTERVENTIONS.125.016270","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter mitral valve-in-valve replacement is an established therapy for intermediate and high-risk patients with degenerated bioprostheses, but restricted transcatheter valve (THV) expansion within rigid surgical frames and elevated gradients have raised durability concerns. This study aimed to evaluate midterm outcomes of mitral valve-in-valve patients according to THV expansion and sizing strategy.</p><p><strong>Methods: </strong>Patients who underwent mitral valve-in-valve with balloon-expandable valves at Mayo Clinic Rochester between 2014 and 2023 were retrospectively analyzed. THV expansion (inflow, waist, outflow) was measured from procedural fluoroscopy and indexed to nominal size, with zero indicating expansion to nominal dimensions. Median index values were used as subgroup cutoffs to compare the incidence of the primary composite outcome of all-cause mortality, heart failure readmission, and valve reintervention.</p><p><strong>Results: </strong>The analysis included 80 patients with a median follow-up of 2.5 years. A total of 53 (66%) valves were underexpanded across all 3 sizes, with median inflow, waist, and outflow expansion indices of -10.2, -16.2, and -3.2, respectively. Across all indices, THV expansion closer to nominal size was associated with lower rates of the primary outcome (<i>P</i><0.05). Greater expansion correlated with a larger mitral valve area and lower transvalvular mean gradient. Oversized THVs were significantly less expanded and had a higher incidence of the primary composite outcome compared with recommended-size THVs (<i>P</i>=0.02).</p><p><strong>Conclusions: </strong>THV underexpansion in degenerated mitral bioprostheses is common and associated with elevated gradients and worse midterm outcomes. Further research is warranted to define THV expansion targets and improve outcomes following mitral valve-in-valve intervention.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016270"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seeing More With Less: AI to Reduce Radiation Exposure in the Cath Lab.","authors":"Thomas Meredith, Celina M Yong, William F Fearon","doi":"10.1161/CIRCINTERVENTIONS.126.016980","DOIUrl":"10.1161/CIRCINTERVENTIONS.126.016980","url":null,"abstract":"","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e016980"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148216699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}